Primary Cicatricial Alopecia

    Chantal Bolduc, Leonard C. Sperling, Jerry Shapiro
    Image of study
    TLDR The document concludes that early recognition and treatment of primary cicatricial alopecia is crucial to prevent permanent hair loss.
    The document from December 2016 provides a comprehensive overview of primary cicatricial alopecia (PCA), detailing the clinical presentation, diagnosis, and management of various forms of PCA. It describes Pseudopelade of Brocq, Central centrifugal cicatricial alopecia, Alopecia mucinosa, and Keratosis follicularis spinulosa decalvans, highlighting their unique characteristics and recommended treatments, which often include topical and intralesional corticosteroids, hydroxychloroquine, and other medications. Additionally, the document covers folliculitis decalvans, dissecting cellulitis, and folliculitis keloidalis, noting their prevalence in certain demographics, clinical features, and the effectiveness of treatments like systemic antibiotics, isotretinoin, and laser hair removal. Histological features of PCAs are described, and management strategies are discussed, including the use of antibacterial shampoos, topical antibiotics, ITA injections, cryotherapy, retinoids, and surgical options. The document stresses the importance of early recognition and management of PCAs to prevent permanent hair loss and improve patient outcomes.
    Discuss this study in the Community →

    Research cited in this study

    49 / 49 results

    Related Community Posts Join

    6 / 290 results
      Diffuse hair loss and scalp biopsies

      community Diffuse hair loss and scalp biopsies

      in Research  692 upvotes 4 months ago
      Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

      in Research/Science  134 upvotes 8 months ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

      community We need to keep these snake oil companies accountable.

      in Treatment  121 upvotes 6 months ago
      Biotin is being misleadingly marketed as a primary treatment for androgenic alopecia, overshadowing more effective treatments like finasteride and minoxidil. There is a call for increased awareness and accountability to prevent misinformation.

    Related Research

    1 / 1 results